Secondary Circulating Prostate Cell Positive Minimal Residual Disease Predict Biochemical Failure in Prostate Cancer Patients after Radical Prostatectomy| Chapter 3 | Perspective of Recent Advances in Medical Research Vol. 1

 The ghost of circulating prostate cells (CPCs), individual subtype of minimal residual affliction, may be useful to call patients at risk for biochemical collapse (BF). The frequency of CPCs discovered following radical prostatectomy (RP), their connection with clinicopathological characteristics, and their equivalence with biochemical disappointment are all discussed.Following RP, serial ancestry samples were collected, mononuclear cells were unique using differential coagulate centrifugation, and CPCs were detected using antagonistic-PSA monoclonal antibodies in accordance with standard immunocytochemistry. The unadjusted biochemical failure free continuation of patients with and outside CPCs was compared using Kaplan Meier methods. In the study, which included 114 brothers, secondary CPCs were found often in patients with helpful margins, extracapsular extension, and vascular and languid infiltration. These judgments also showed a smaller time to BF and an association middle from two points biochemical failure independent of these clinicopathological variables. Secondary CPCs are an free risk factor for higher BF in brothers with a PSA <0.2 ng/mL following radical prostatectomy, but they do not distinguish between local and fundamental disease recurrence.

Author(s) Details:

Nigel P. Murray,
Division of Medicine, Hospital de Carabineros de Chile, Simon Bolivar 2200, Nunoa, 7770199, Santiago, Chile and Faculty of Medicine, Universiyt Finis Terrae, Providencia, Santiago, Chile.

Eduardo Reyes,
Faculty of Medicine, Universidad Diego Portales, Manuel Rodriguez Sur 415, 8370179, Santiago, Chile and Urology Division, Hospital de Carabineros de Chile, Simon Bolivar 2200, Nunoa, 7770199, Santiago, Chile.

Nelson Orellana,
Urology Division, Hospital de Carabineros de Chile, Simon Bolivar 2200, Nunoa, 7770199, Santiago, Chile.

Cynthia Fuentealba,
Carabineros de Chile, Simon Bolivar 2200, Nunoa, 7770199, Santiago, Chile.

Leonardo Badinez,
Foundation Arturo Lopez Perez, Rancagua 899, Providencia, 7500921, Santiago, Chile.

Ruben Olivares,
Urology Division, Hospital de Carabineros de Chile, Simon Bolivar 2200, Nunoa, 7770199, Santiago, Chile.

Jose Porcell,
Division of Medicine, Hospital de Carabineros de Chile, Simon Bolivar 2200, Nunoa, 7770199 Santiago, Chile.

Ricardo Duenas,
Urology Division, Hospital de Carabineros de Chile, Simon Bolivar 2200, Nunoa, 7770199, Santiago, Chile.

Please see the link here: https://stm.bookpi.org/PRAMR-V1/article/view/8998

An Overview of Early Response to Dexamethasone as Prognostic Factor: Result from Indonesian Childhood WK-ALL Protocol in Yogyakarta | Chapter 14 | Research Trends and Challenges in Medical Science Vol. 2

Early response to treatment has been shown to be an important prognostic factor of childhood acute lymphoblastic leukemia (ALL) patients in Western studies. We studied this factor in the setting of a low-income province in 165 patients treated on Indonesian WK-ALL-2000 protocol between 1999 and 2006. Poor early response, defined as a peripheral lymphoblasts count of ≥1000/µL after 7 days of oral dexamethasone plus one intrathecal methotrexate (MTX), occurred in 19.4% of the patients. Poor responders showed a higher probability of induction failures compared to good responders (53.1% versus 23.3%, P < 0.01), higher probability of resistant disease (15.6% versus 4.5%, P = 0.02), shorter disease-free survival (P = 0.034; 5-year DFS: 24.9% ± 12.1% versus 48.6% ± 5.7%), and shorter event-free survival (P = 0.002; 5-year EFS: 9.7% ± 5.3% versus 26.3% ± 3.8%). We observed that the percentage of poor responders in our setting was higher than reported for Western countries with prednisone or prednisolone as the steroids. The study did not demonstrate a significant additive prognostic value of early response over other known risk factors (age and white blood cell count) for DFS and only a moderately added value for EFS. 

Author(s) Details

Pudjo H. Widjajanto
Pediatric Hematology and Oncology Division, Department of Pediatrics, Dr. Sardjito Hospital/ Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.

Sutaryo Sutaryo
Pediatric Hematology and Oncology Division, Department of Pediatrics, Dr. Sardjito Hospital/ Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia

Ignatius Purwanto
Pediatric Hematology and Oncology Division, Department of Pediatrics, Dr. Sardjito Hospital/ Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia

View Book :- http://bp.bookpi.org/index.php/bpi/catalog/book/190